Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH)
agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer
in patients treated by radical prostatectomy without a survival benefit. There is no evidence
yet of a survival impact of LHRH antagonist (LHRHa) +/- new-generation anti-androgens in this
setting. Thus novel studies are needed to assess this treatment combination.
PURPOSE: To assess the difference in treatment antitumor effect between arms by measuring
pathological tumor volume with minimal residual disease (MRD) following radical prostatectomy
+ pelvic lymph-node dissection (RP + PLND) for intermediate or high-risk prostate cancer
patients.